Related Experiment Video
Updated: Jul 9, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
[Factor Xa-inhibition in interventional cardiology]
1Centre for Thrombosis & Myocardial Infarction, Baker Heart Research Institute, St Kilda Road Central, Melbourne, Victoria 8008, Australia. ingo.ahrens@baker.edu.au
Hamostaseologie
|December 7, 2007
Summary
Safer anticoagulants are needed for acute coronary syndromes (ACS) patients on antiplatelet therapy. Selective factor Xa inhibitors show promise for improving outcomes in ST-elevation myocardial infarction (STEMI) and other ACS cases.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Context:
- Bleeding events in acute coronary syndromes (ACS) patients correlate with poor clinical outcomes.
- Current anticoagulants (unfractionated heparin, low molecular weight heparins) have limitations.
- There is an unmet need for safer anticoagulants for patients on dual or triple antiplatelet therapy.
Purpose:
- To discuss the pharmacology of selective factor Xa inhibitors.
- To review indirect and direct selective factor Xa inhibitors.
- To explore their role in interventional cardiology for ACS patients.
Summary:
- Coagulation factors IIa and Xa are key targets for anticoagulants.
- New agents selectively inhibit factor Xa, offering potential safety benefits.
- Indirect selective factor Xa inhibitors (Fondaparinux, Idraparinux) and direct selective factor Xa inhibitors (DX-9065a, Otamixaban) are discussed.
Impact:
- Selective factor Xa inhibitors may offer improved safety profiles compared to traditional anticoagulants.
- These agents could enhance clinical outcomes for ACS patients, particularly those undergoing invasive procedures.
- Further research into selective factor Xa inhibitors is crucial for advancing anticoagulant therapy in cardiology.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...